Elfatih O Elzein

This inventor holds 87 USPTO granted patents and 10 published patent applications, plus 4 CIPO patents and 18 EPO patents, primarily in Adenosine Receptor Modulators (CPC class C07D413-14). Top assignees: Cv Therapeutics, Inc., Gilead Sciences, Inc., Gilead Palo Alto, Inc.. Active years: 2001-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Elfatih O Elzein. Retrieved from https://idiyas.com/inventor/elfatih-o-elzein

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 87 (Patent Applications = 10)

% Patents Active = 62.1

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 18 (Patent Applications = 17)

Average Co-Inventor Count = 4.5

ph-index = 20

Forward Citations = 884(Granted Patents)

Forward Citations (Not Self Cited) = 556(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Freemont, CA (US) (2001 - 2009)
Foster City, CA (US) (2013)
Fremont, CA (US) (2002 - 2019)
Mountain House, CA (US) (2018 - 2022)
Redwood City, CA (US) (2023 - 2024)

Company Filing History:

46 out of 105

Cv Therapeutics, Inc.

patents

30 out of 946

Gilead Sciences, Inc.

patents

8 out of 15

Gilead Palo Alto, Inc.

patents

4. 3 out of 3

Teon Therapeutics, Inc.

patents

5. 1 out of 10

The Endowment for Research in Human Biology, Inc.

patents

where one patent can have more than one assignee

Years Active: 2001-2024

Loading Chart...

Areas of Expertise:

Adenosine Receptor Antagonists

Cannabinoid Receptor Modulators

Fused Heterocyclic Compounds

Ion Channel Modulators

Therapeutic Compounds

CaM Kinase Inhibitors

Heterocyclic Compounds

A2A Receptor Agonists

ALDH-2 Inhibitors

N-Pyrazole Compounds

A2B Receptor Antagonists

Pharmaceutical Applications

87 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11957689 - Cannabinoid receptor type 2 (CB2) modulators and uses thereof (2024-04-16),

2. 11564928 - Cannabinoid receptor type 2 (CB2) modulators and uses thereof (2023-01-31),

3. 11229638 - Therapeutic heterocyclic compounds (2022-01-25),

4. 11124515 - Adenosine receptor antagonists and uses thereof (2021-09-21),

5. 11098027 - Therapeutic heterocyclic compounds (2021-08-24),

6. 11040033 - Therapeutic heterocyclic compounds (2021-06-22),

7. RE47351 - 2-(N-pyrazolo)adenosines with application as adenosine Areceptor agonists (2019-04-15),

8. RE47301 - Process for preparing an A2A-adenosine receptor agonist and its polymorphs (2019-03-18),

9. 10100058 - Fused heterocyclic compounds as CaM kinase inhibitors (2018-10-16),

10. 9695192 - Fused heterocyclic compounds as ion channel modulators (2017-07-04),

11. 9682998 - Fused heterocyclic compounds as ion channel modulators (2017-06-20),

12. 9676760 - Fused heterocyclic compounds as ion channel modulators (2017-06-13),

13. 9598435 - Fused heterocyclic compounds as ion channel modulators (2017-03-21),

14. 9403782 - Fused heterocyclic compounds as ion channel modulators (2016-08-02),

15. 9371329 - Fused heterocyclic compounds as ion channel modulators (2016-06-21),

Title: The Innovative Journey of Inventor Elfatih O Elzein

Introduction: Elfatih O Elzein is a pioneering inventor based in Fremont, California. With a passion for creating groundbreaking solutions, Elzein has made significant contributions to the field of technology through his inventive spirit and dedication to innovation.

Latest Patents: Elzein's latest patents showcase his commitment to pushing the boundaries of technology. His recent inventions have focused on enhancing efficiency in renewable energy systems and improving data security protocols in the digital realm.

Career Highlights: Throughout his illustrious career, Elzein has been recognized for his innovative approach to problem-solving. His work has garnered acclaim for its practical applications and forward-thinking design, earning him a reputation as a visionary in the tech industry.

Collaborations: Elzein has collaborated with leading tech companies and research institutions to bring his inventions to life. His partnerships have been instrumental in bridging the gap between cutting-edge technology and real-world implementation, paving the way for a more connected and sustainable future.

Conclusion: In conclusion, Elfatih O Elzein's inventive prowess and unwavering dedication to innovation have established him as a trailblazer in the field of technology. His contributions continue to inspire and shape the future of technological advancement, leaving a lasting impact on industries around the world.

Profile summary based on public USPTO records.